The 2012 ICAAC Young Investigator Award designated for a researcher working in the area of HIV has been bestowed upon Mario L. Santiago, Ph.D., Division of Infectious Diseases, University of Colorado, Denver. Santiago is honored for his varied work in virology, from field-based HIV epidemiology studies to manipulating innate immunity in his efforts to explore innovative new ways to approach the challenge of the HIV vaccine. "Already at this early stage of his career, Santiago is demonstrating that he is one of the upcoming leaders in the field of retroviral resistance genes and their fascinating mechanisms of action," explains Kim Hasenkrug, Rocky Mountain Laboratories, NIAID.
Santiago graduated from the University of the Philippines magna cum laude with a BS in Molecular Biology and Biotechnology. He then worked on schistosome and malaria vaccines as part of the NIH-sponsored Tropical Medicine Research Center in the Philippines and on HIV-1 molecular epidemiology as a Fogarty AIDS International Research fellow at Brown University. Santiago went on to receive his Ph.D. in Microbiology under Beatrice Hahn at the University of Alabama-Birmingham, where he developed noninvasive methods to detect Simian Immunodeficiency Virus in wild nonhuman primates, eventually leading to the discovery of the origins of HIV-1 and HIV-2 in wild chimpanzees and sooty mangabeys, respectively. "During his tenure, he painstakingly designed, tested and optimized strategies to noninvasively screen fecal and urine samples from wild monkeys and great apes for simian immunodeficiency viruses, which aided in our breakthrough understanding of the origins of HIV-1 and HIV-2," explains Hahn. "These findings resulted in fascinating high-profile publications and have revolutionized our perspective on the AIDS pandemic."
After receiving his Ph.D., Santiago completed two postdoctoral fellowships, first at the University of Alabama-Birmingham, then at the Gladstone Institute for Virology and Immunology at the University of California, San Francisco, where he discovered that a long-sought classical resistance gene that modulates the retrovirus-specific neutralizing antibody response known as Rfv3 corresponds to an innate immunity gene known as APOBEC3. In 2006, Santiago reached out to Hasenkrug to collaborate: "he emailed me with the hypothesis that a retroviral resistance gene that I had mapped (Rfv3), might be Apobec3. He trained briefly in my lab, learned the mouse retrovirus model very quickly, and in short order had the model working at the Gladstone Institute. He has pushed this research forward, innovating new techniques and technologies, and has opened the door to a very exciting and highly competitive research area."
In 2009, Santiago joined the Division of Infectious Diseases at the University of Colorado Denver-Anschutz Medical Campus. There he continues his work on the interplay between innate retroviral restriction and adaptive immunity in mice, monkeys and humans, with a conceptual focus on HIV vaccine development, host genetics of retrovirus resistance, and interferon-based antiretroviral therapy. He currently supervises a post-doctoral fellow and three graduate students from the Immunology and Microbiology programs, where he holds adjunct appointments.
Santiago's scientific contributions have been published in prominent journals that include Science, Nature, Cell, PNAS, PLoS Pathogens, and The Journal of Virology. "Santiago's recent work on the function of human Apobec3 has helped delineate potential genetic mechanisms behind the production of neutralizing antibodies to HIV, which are critical to preventing HIV infection," says nominator Thomas Campbell, University of Colorado, Denver. "His research findings will help to inform the discovery of HIV drugs and vaccines." He concludes, "Santiago's outstanding achievements attest to his creativity and collegiality, and his exceptional ability to successfully accomplish innovative, cutting-edge research in retrovirology."
The ICAAC Young Investigator Award will be presented during ASM's 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 9-12, 2012 in San Francisco, CA. ASM is the world's oldest and largest life science organization and has more than 40,000 members worldwide. ASM's mission is to advance the microbiological sciences and promote the use of scientific knowledge for improved health, economic, and environmental well-being.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.